a meaningful CFU count (1015 billion or more)
Originally developed for T2D, these agents enhance insulin sensitivity by reducing insulin resistance, as demonstrated by significant declines in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) scores
By leveraging the anti-inflammatory effects of both BPC-157 and VIP, this peptide combination shows promise in addressing inflammatory conditions, promoting tissue healing, and supporting overall wellness
A 2025 meta-analysis found that semaglutide increased the relative risk of cholelithiasis (gallstones) by 1.92 , liraglutide by 1.75 , and tirzepatide by 1.36
ElahiDMcAloon-DykeMFukagawaNKMeneillyGSSclaterALMinakerKLet al
Considering that the pharmacy benefit manager CVS Caremark removed its coverage for Zepbound in July, its likely that more people will consider microdosing to help stretch out those very expensive prescriptions